This page brings together the Agency's latest information on cancer. It lists:
This is a summary of the European public assessment report (EPAR) for Thyrogen. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Kadcyla. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
Imbruvica is a medicine for treating adult patients with the following blood cancers: mantle cell lymphoma in patients whose disease does not respond to or has come back after previous treatment;...
This is a summary of the European public assessment report (EPAR) for Akynzeo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
Revlimid is a medicine used for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma, myelodysplastic syndromes and mantle cell and...
EMA’s safety committee (PRAC) has confirmed its recommendation to limit the use of high-strength creams containing 100 micrograms/gram (0.01%) of estradiol to a single treatment period of up to 4‑weeks. This follows a re-examination of its...
EMA is recommending that patients stop using Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, while it continues its review of the medicine’s safety. EMA’s safety committee (PRAC) is currently reviewing data on...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2019 meeting. The Committee recommended granting a marketing authorisation for Beovu (brolucizumab) for the...
Seven new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2019 meeting. The Committee recommended granting a marketing authorisation for Isturisa * (osilodrostat) for...
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Vitrakvi (larotrectinib) for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine...
EMA’s safety committee (PRAC) is recommending new measures to avoid dosing errors that have led to some patients incorrectly taking methotrexate-containing medicines daily instead of weekly. The new measures include restricting who can prescribe...
The aim of the workshop is to investigate the feasibility of using disease registries for cancer...
The innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full...
The third multi-stakeholder Paediatric Strategy Forum, jointly organised by EMA and ACCELERATE will...
The main objective of this workshop organised by the European Medicines Agency (EMA), RD-ACTION (...